Market Overview - The three major U.S. stock indices closed lower, with the Nasdaq down 2.15%, the S&P 500 down 1.67%, and the Dow Jones down 1.72%, marking the fifth consecutive week of declines for all indices [2][4]. - The Nasdaq's closing price was nearly 13% lower than its record high from October 2025, while the Dow fell into a correction zone, down 10% from recent highs [4]. Commodity Market Dynamics - A shift in the commodity market was noted, with both oil and gold prices rising simultaneously, contrasting the previous trend of "oil up, gold down" [5][6]. - Gold futures rose by 2.66% to $4,526 per ounce, silver futures increased by 3% to $69.97 per ounce, and U.S. oil prices surged over 7% to $101.16 per barrel [7][8]. Gold Market Insights - Analysts suggest that gold is regaining its appeal as a value investment, especially after a period of being viewed as a liquid asset amid market volatility [9]. - Deutsche Bank raised its gold price forecast for the end of the year from $4,900 to $5,000 per ounce, indicating that recent price corrections may not last [10]. Technology Sector Performance - Major technology stocks experienced significant declines, with the "MAG7" index dropping 2.78%. Notable declines included Amazon down nearly 4% and Meta down 3.99%, marking an 11.63% drop over two days [12][14]. - Meta's stock was pressured by legal issues and concerns over future profitability, including a $375 million fine related to child protection and potential liabilities from social media addiction cases [15]. Inflation and Geopolitical Risks - High oil prices are suppressing risk assets through both cost and expectation channels, with international oil prices reaching three-year highs amid geopolitical tensions [16][17]. - The market has abandoned expectations for interest rate cuts by the Federal Reserve this year, with a 54% probability of at least one rate hike anticipated [17]. - The ongoing conflict in the Middle East is expected to exacerbate inflation concerns, complicating the outlook for central banks globally [17][18].

Core Viewpoint - Class action lawsuits have been filed on behalf of shareholders of several publicly-traded companies, with deadlines for filing lead plaintiff motions approaching [1] Group 1: F5, Inc. (NASDAQ: FFIV) - The class period for F5, Inc. is from October 28, 2024, to October 27, 2025, with a lead plaintiff deadline of February 17, 2026 [2] - The complaint alleges that F5's management made materially false and misleading statements and failed to disclose a significant security incident that jeopardized client security and the company's future prospects [2] Group 2: SLM Corporation (NASDAQ: SLM) - The class period for SLM Corporation is from July 25, 2025, to August 14, 2025, with a lead plaintiff deadline of February 17, 2026 [3] - The complaint claims that SLM's management failed to disclose a significant increase in early-stage delinquencies and overstated the effectiveness of its loss mitigation programs, leading to materially misleading statements about the company's stability [3] Group 3: Charming Medical Limited (NASDAQ: MCTA) - The class period for Charming Medical Limited is from October 10, 2025, to November 12, 2025, with a lead plaintiff deadline of February 17, 2026 [4] - The complaint alleges that Charming was involved in a fraudulent stock promotion scheme and that insiders facilitated the dumping of shares during a price inflation campaign, resulting in materially misleading statements about the company's operations [4] Group 4: Klarna Group plc (NYSE: KLAR) - The class period for Klarna Group plc is from September 7, 2025, to December 22, 2025, with a lead plaintiff deadline of February 20, 2026 [5] - The complaint states that Klarna's management materially understated the risk of increased loss reserves shortly after the IPO, leading to misleading statements about the company's business and operations [5][6]

Group 1 - The article highlights the upcoming deadline of February 17, 2026, for investors to file a lead plaintiff motion in a case concerning Charming Medical Limited (NASDAQ: MCTA) [1] - The case is filed on behalf of investors who purchased Charming Medical Limited securities during the class period from October 10, 2025, to November 12, 2025 [1] - Investors who suffered losses in Charming Medical Limited are encouraged to contact the Law Offices of Howard G. Smith for assistance [1]

Group 1 - The article discusses a class action lawsuit against Charming Medical Limited (MCTA) for securities fraud, with a deadline for shareholders to file a lead plaintiff motion by February 17, 2026 [1] - The lawsuit claims that during the class period from October 10, 2025, to November 12, 2025, the company made materially false and misleading statements regarding its business and operations [1] - The SEC halted trading of Charming securities on November 11, 2025, due to potential manipulation through social media recommendations aimed at artificially inflating the stock price [1] Group 2 - Allegations in the lawsuit include that insiders used offshore accounts to facilitate the dumping of shares during a price inflation campaign, and that the company failed to disclose material adverse facts [1] - The complaint asserts that the company's public statements omitted any mention of false rumors and artificial trading activity that influenced the stock price [1] - Shareholders who acquired Charming securities during the class period are encouraged to participate in the lawsuit to recover losses under federal securities laws [1]

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ:MCTA) for alleged fraudulent activities related to stock promotion schemes that misled investors during the Class Period from October 10, 2025, to November 12, 2025 [7]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [7]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [7]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [7]. Stock Performance - Charming's share price increased from the initial public offering price of $4.00 to an all-time high of $29.36 per share prior to November 12, 2025, despite no fundamental news justifying such a rise [7]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [7]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the necessary information to lift the suspension [7].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotion schemes that misled investors during the period from October 10, 2025, to November 12, 2025 [7]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [7]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [7]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [7]. Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [7]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [7]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the necessary information to lift the suspension [7].

Core Viewpoint - A class action lawsuit has been filed against Charming Medical Limited (NASDAQ: MCTA) for alleged fraudulent activities related to stock promotion schemes that misled investors during the period from October 10, 2025, to November 12, 2025 [8]. Allegation Details - The lawsuit claims that Charming failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [8]. - Insiders allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [8]. - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that inflated the stock price [8]. Stock Performance - Charming's share price increased from an initial public offering price of $4.00 to a peak of $29.36 per share, despite no fundamental news justifying such a rise [8]. - Investigations revealed that the stock was subject to an illicit promotion scheme that artificially inflated its price through sensational claims made by impersonators in online forums and social media [8]. Regulatory Actions - On November 12, 2025, the SEC halted trading of Charming's stock, which remains suspended as the company has not provided the required information to lift the suspension [8].

Core Viewpoint - A lawsuit is pending against Charming Medical Limited (NASDAQ: MCTA) for alleged violations of securities laws, with a deadline for affected investors to act by February 17, 2026 [1]. Group 1: Lawsuit Details - An investor filed a lawsuit on December 22, 2025, claiming that Charming Medical made false and misleading statements and failed to disclose involvement in a fraudulent stock promotion scheme [2]. - The lawsuit alleges that insiders and affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - It is claimed that Charming Medical's public statements and risk disclosures did not mention the false rumors and artificial trading activity that influenced the stock price [2]. Group 2: Investor Actions - Investors who purchased shares of Charming Medical Limited are encouraged to contact the Shareholders Foundation for assistance [3]. - The Shareholders Foundation provides legal monitoring and settlement claim filing services related to shareholder issues and securities class actions [3].

Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for alleged fraudulent stock promotion activities that misled investors and artificially inflated the company's stock price [1][2]. Allegations - The complaint alleges that Charming Medical was involved in a fraudulent stock promotion scheme that included misinformation on social media and impersonation of financial professionals [2]. - Insiders and affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2]. - The company's public statements and risk disclosures failed to mention the false rumors and artificial trading activity that were driving the stock price [2]. Stock Price Movement - In the weeks leading up to November 12, 2025, Charming's share price increased from the initial public offering price of $4.00 to a peak of $29.36 per share, despite a lack of fundamental news justifying such a rise [3]. - Investigations revealed that the stock was subject to an illicit promotion scheme that created a buying frenzy among retail investors through sensational claims made by impersonators on social media [3]. - Trading of Charming's stock was halted by the SEC on November 12, 2025, and remains suspended due to the company's failure to provide required information to regulators [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by February 17, 2026 [4]. - Participation in the case is not required to be eligible for recovery, and shareholders can choose to remain absent class members [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless a recovery is achieved [5].

Core Viewpoint - A class action has been filed against Charming Medical, Limited (NASDAQ: MCTA) for allegedly engaging in a fraudulent stock promotion scheme that misled investors and artificially inflated its stock price [1][2][3] Allegations - The complaint alleges that Charming Medical failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals [2] - Insiders and/or affiliates reportedly used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [2] - The company's public statements and risk disclosures did not mention the false rumors and artificial trading activity that were driving the stock price [2] Stock Price Surge - In the weeks leading up to November 12, 2025, Charming's share price increased from the initial public offering price of $4.00 to a peak of $29.36 per share, despite a lack of fundamental news justifying such a rise [3] - Investigations revealed that the stock was subject to an illicit promotion scheme that created a buying frenzy among retail investors through sensational but unfounded claims made by impersonators posing as legitimate financial advisors [3] - Trading of Charming's stock was halted by the SEC on November 12, 2025, and remains suspended due to the company's failure to provide required information to regulators [3] Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit papers to the court by February 17, 2026, and do not need to participate in the case to be eligible for recovery [4] - Absent class members can choose not to take action while still being eligible for potential recovery [4] Legal Representation - All representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]